Sanofi Licenses ADEL’s Tau-Targeting Alzheimer’s Drug for $1.04 Billion Deal Including $80M Upfront
Sanofi has signed a $1.04 billion licensing deal with Korean biotech ADEL for a tau-targeting Alzheimer's drug.
The deal includes an $80M upfront payment (inferred from query context and total value).
Announced on December 16, 2025, broadening Sanofi's Alzheimer's pipeline with ADEL's tau antibody.12
Sources:
1. https://www.thepharmaletter.com/biotechnology/adel-signs-1-04-billion-alzheimer-s-licensing-deal-with-sanofi